Vertex Pharmaceuticals (NQ:VRTX)

501.93 -1.57 (-0.31%)

Delayed Quote Updated: 3:51 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

77 78 Next >

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis

July 02, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

3 Under-the-Radar Biotech Stocks With Blockbuster Potential ↗

July 02, 2024

Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three.

Via InvestorPlace

Vertex to Announce Second Quarter 2024 Financial Results on August 1

July 01, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today ↗

July 01, 2024

Via Benzinga

Peering Into Vertex Pharmaceuticals's Recent Short Interest ↗

June 26, 2024

Via Benzinga

Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX. ↗

June 20, 2024

NASDAQ:VRTX is not too expensive for the growth it is showing.

Via Chartmill

3 Breakout Biotech Stocks on Track to Double by 2032 ↗

July 01, 2024

The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.

Via InvestorPlace

Bull Market Buys: 2 Growth Stocks to Own for the Long Run ↗

July 01, 2024

The latest bull market has plenty of intriguing buying opportunities.

Via The Motley Fool

2 Superior Growth Stocks to Buy if You Have $1,000 Right Now ↗

June 28, 2024

Growth stocks with wide moats and strong financials can compound investor returns with time.

Via The Motley Fool

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

June 28, 2024

These healthcare stocks have clear paths to growth over the next few years.

Via The Motley Fool

2 Healthcare Stocks That Are Screaming Buys in June ↗

June 28, 2024

These top healthcare stocks are no-brainer buys in 2024 and beyond.

Via The Motley Fool

You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever. ↗

June 27, 2024

Invest in the top biotech stocks to buy, as the sector pivots from pandemic-driven vaccine sales to solutions for chronic conditions.

Via InvestorPlace

13 Analysts Have This To Say About Vertex Pharmaceuticals ↗

June 17, 2024

Via Benzinga

Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)? ↗

June 12, 2024

Why NASDAQ:VRTX Stands Out as a Quality Stock.

Via Chartmill

This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

June 27, 2024

Via Benzinga

Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued." ↗

June 27, 2024

The biotech's shares have traded sideways for over a year, but better days could be on the near-term horizon.

Via The Motley Fool

3 Biotech Stocks That Could Make Your Grandchildren Rich ↗

June 27, 2024

These biotech stocks are poised to generate significant returns to investors due to their high growth potential.

Via InvestorPlace

Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy? ↗

June 25, 2024

It looks like Vertex's experimental new therapy could become a functional cure for lots of people with diabetes.

Via The Motley Fool

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions

June 21, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead ↗

June 21, 2024

Lilly is a good pick...but this one is better.

Via The Motley Fool

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗

June 18, 2024

Via Benzinga

3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation ↗

June 18, 2024

Evergreen business models make it easier to hold for the long run.

Via The Motley Fool

Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades' ↗

June 17, 2024

On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having...

Via Benzinga

3 Growth Stocks You Can Buy Right Now Without Any Hesitation ↗

June 15, 2024

Want peace of mind about your investments? Consider these great stocks.

Via The Motley Fool

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress

June 14, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Healthcare Stocks to Buy Hand Over Fist in June ↗

June 12, 2024

They both have pretty impressive pasts, and their prospects look just as bright.

Via The Motley Fool

Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 11, 2024

Via Benzinga

Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO ↗

June 10, 2024

Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services.

Via Talk Markets

Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought ↗

June 09, 2024

These companies could generate explosive growth over time.

Via The Motley Fool

Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst ↗

June 07, 2024

Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.